Evidence map›Paper›PMID 40468406›Full record

ReviewCell & bioscience2025

Domain acquisition enabled functional expansion of the TFIIS transcription factor family.

Kateryna Matveyeva, Ainhoa Sánchez de Diego, María Ángeles García-López, Julio Gutiérrez, Thierry Fischer, Karel H M van Wely

Abstract readReview
In one paragraph

Review in Cell & bioscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kateryna MatveyevaCentro Nacional de Biotecnologia - CSIC, C/ Darwin, 3, Madrid, 28049, Spain.ORCID https://orcid.org/0009-0008-1698-2789
Ainhoa Sánchez de DiegoCentro Nacional de Biotecnologia - CSIC, C/ Darwin, 3, Madrid, 28049, Spain.ORCID https://orcid.org/0000-0001-6299-7588
María Ángeles García-LópezCentro Nacional de Biotecnologia - CSIC, C/ Darwin, 3, Madrid, 28049, Spain.ORCID https://orcid.org/0000-0002-1417-9385
Julio GutiérrezCentro Nacional de Biotecnologia - CSIC, C/ Darwin, 3, Madrid, 28049, Spain.ORCID https://orcid.org/0000-0002-2212-064X
Thierry FischerCentro Nacional de Biotecnologia - CSIC, C/ Darwin, 3, Madrid, 28049, Spain.ORCID https://orcid.org/0000-0002-9542-322X
Karel H M van WelyCentro Nacional de Biotecnologia - CSIC, C/ Darwin, 3, Madrid, 28049, Spain. kvanwely@cnb.csic.es.ORCID https://orcid.org/0000-0001-8431-8072

Funding

Ministerio de Ciencia e Innovación PID2022-142616OB-I00Ministerio de Ciencia e Innovación PRE2020-096088
6 · The paper itself

Abstract

TFIIS and its homologs were long considered a delimited family of transcription factors, for the ability to induce RNA Polymerase II backtracking and nascent RNA cleavage. Recent studies however show that the relevant domains, which correspond to the TFIIS middle and carboxyterminal regions, are used to control transcription by additional protein architectures. The TFIIS middle region is paired with a SPOC domain in BYE1, the founder protein of the subfamily, and in its homologs; this combination of domains accommodates additional features such as a small zinc finger resembling the TFIIS carboxyterminal region. In metazoans, the architecture has evolved additional extensions to act on downstream RNA processing. Here, we argue in favor of a single protein superfamily encompassing TFIIS, BYE1, and their metazoan homologs. We conclude that the TFIIS middle domain comprises a common Pol2-interacting domain, shared by various generic protein functions. Domain composition of the vertebrate BYE1 homologs indicates a role in transcription elongation. Depending on the combination with other structures, the TFIIS middle domain may promote mutually exclusive activities, for example backtracking versus RNA synthesis and splicing. In this way, exchange of TFIIS for other superfamily members supports the separate Pol2 actions.

Identifiers

PMID40468406
PMCPMC12139180

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.